Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of heteroaryl isothiazolones in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2445-2453

  Cheng, Jijun ^a   Thanassi, Jane A ^a   Thoma, Christy L ^a   Bradbury, Barton J ^a   Deshpande, Milind ^a   Pucci, Michael J ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ETHIDIUM BROMIDE; GEMIFLOXACIN; ISOTHIAZOLE DERIVATIVE; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; DNA SEQUENCE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; GRLA GENE; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PARC GENE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MUTATION; QUINOLONES; STAPHYLOCOCCUS AUREUS; THIAZOLES;

EID: 34447270724     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00158-07     Document Type: Article

References (50)

1. Barrett, J. F., J. I. Bernstein, H. M. Krause, J. J. Hilliard, and K. A. Ohemeng. 1993. Testing potential gyrase inhibitors of bacterial gyrase: a comparison of the supercoling inhibition assay and "cleavable complex" assay. Anal. Biochem. 214:313-317.
2. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
3. Blondeau, J. M. 2000. Gatifloxacin: a new fluoroquinolone. Expert Opin. Investig. Drugs 9:1877-1895.
4. Blondeau, J. M., R. Laskowski, J. Bjarnason, and C. Stewart. 2000. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int. J. Antimicrob. Agents 14:45-50.
5. Brooun, A., S. Liu, and K. Lewis. 2000. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 44:640-646.
6. Cheng, J., J. A. Thanassi, C. L. Thoma, Y. Ou, B. J. Bradbury, M. Deshpande, and M. J. Pucci. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-1995.
7. Chu, D. T. W., P. B. Fernandes, A. K. Claiborne, L. Shen, and A. G. Pernet. 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res. 14:379-383.
8. Chu, D. T. W., I. M. Lico, A. K. Claiborne, J. J. Plattner, and A. G. Pernet. 1990. Structure-activity relationship of quinolone antibacterial agents: the effects of C-2 substitution. Drugs Exp. Clin. Res. 16:215-224.
9. Clerch, B., E. Rivera, and M. Llagostera. 1996. Identification of a pKM101 region which confers a slow growth rate and interferes with susceptibility to quinolone in Escherichia coli AB1157. J. Bacteriol. 178:5568-5572.
10. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
11. Discotto, L. F., L. E. Lawrence, K. L. Denbleyker, and J. F. Barrett. 2001. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob. Agents Chemother. 45:3273-3275.
12. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin- resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
13. French, G. L. 2005. Clinical impact and relevance of antibiotic resistance. Adv. Drug Deliv. Rev. 57:1514-1527.
14. Furuya, E. Y., and F. D. Lowy. 2006. Antimicrobial-resistant bacteria in the community setting. Nat. Rev. Microbiol. 4:36-45.
15. Gould, I. M. 2005. The clinical significance of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 61:277-282.
16. Griggs, D. J., H. Marona, and L. J. Piddock. 2003. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J. Antimicrob. Chemother. 51:1403-1407.
17. Hancock, R. E. 2005. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect. Dis. 5:209-218.
18. Heisig, P. 2001. Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects. Planta Med. 67:3-12.
19. Hooper, D. C. 2002. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2:530-538.
20. Hooper, D. C. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32:S9-S15.
21. Hooper, D. C. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 2:S24-S28.
22. Horii, T., Y. Suzuki, A. Monji, M. Morita, H. Muramatsu, Y. Kondo, M. Doi, A. Takeshita, T. Kanno, and M. Maekawa. 2003. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn. Microbiol. Infect. Dis. 46:139-145.
23. Ince, D., X. Zhang, and D. C. Hooper. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415.
24. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2003. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:274-282.
25. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350.
26. Jones, R. N., M. L. Beach, M. A. Pfaller, and G. V. Doern. 1998. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Diagn. Microbiol. Infect. Dis. 32:247-252.
27. Low, D. E., M. Muller, C. L. Duncan, B. M. Willey, J. C. de Azavedo, A. McGeer, B. N. Kreiswirth, S. Pong-Porter, and D. J. Bast. 2002. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Antimicrob. Agents Chemother. 46:1119-1121.
28. MacGowan, A. P. 1999. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin. Investig. Drugs 8:181-199.
29. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, D. A. Talan, and EMERGEncy ID Net Study Group. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
30. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
31. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
32. Noguchi, N., T. Okihara, Y. Namiki, Y. Kumaki, Y. Yamanaka, M. Koyama, K. Wakasugi, and M. Sasatsu. 2005. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int. J. Antimicrob. Agents 25:374-379.
33. Peeters, M. J., and J. C. Sarria. 2005. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am. J. Med. Sci. 330:102-104.
34. Pucci, M. J., J. Cheng, S. D. Podos, C. L. Thoma, J. A. Thanassi, D. D. Buechter, G. Mushtaq, G. A. Vigliotti, Jr., B. J. Bradbury, and M. Deshpande. 2007. In vitro and in vivo antibacterial activities of isothiazoloquinolones against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 51:1259-1267.
35. Rice, L. B. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Med. 119(Suppl. 1):S11-S19; discussion, S62-S70.
36. Roychoudhury, S., and B. Ledoussal. 2002. Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens. Curr. Drug Targets Infect. Disord. 2:51-65.
37. Schweon, S. J. 2006. MRSA extends its reach. RN 69:33-34,36; quiz, 37.
38. Shah, P. M. 2005. The need for new therapeutic agents: what is the pipeline? Clin. Microbiol. Infect. 11(Suppl. 3):36-42.
39. Sheldon, A. T., Jr. 2005. Antibiotic resistance: a survival strategy. Clin. Lab. Sci. 18:170-180.
40. Sierra, J. M., J. G. Cabeza, M. Ruiz Chaler, T. Montero, J. Hernandez, J. Mensa, M. Llagostera, and J. Vila. 2005. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11:750-758.
41. Skiest, D. J. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656.
42. Strahilevitz, J., Y. Onodera, and D. C. Hooper. 2006. An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr. Purif. 47:10-15.
43. Strahilevitz, J., A. Robicsek, and D. C. Hooper. 2006. Role of the extended α4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob. Agents Chemother. 50:600-606.
44. Takei, M., H. Fukuda, R. Kishii, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
45. Trucksis, M., J. S. Wolfson, and D. C. Hooper. 1991. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J. Bacteriol. 173: 5854-5860.
46. Truong-Bolduc, Q. C., J. Strahilevitz, and D. C. Hooper. 2006. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1104-1107.
47. Truong-Bolduc, Q. C., P. M. Dunman, J. Strahilevitz, S. J. Projan, and D. C. Hooper. 2005. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J. Bacteriol. 187:2395-2405.
48. Truong-Bolduc, Q. C., X. Zhang, and D. C. Hooper. 2003. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J. Bacteriol. 185:3127-3138.
49. Yamagishi, J.-I., T. Kojima, Y. Oyamada, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163.
50. Zhao, X., W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica. 2003. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1023-1027.